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Abstract
Invasive pneumococcal infection is a major cause of morbidity and mortality worldwide
despite the availability of pneumococcal vaccines. The aim of this study was to re-evaluate
the clinical syndromes, prognostic factors and outcomes for pneumococcal disease in
adults and children in Singapore during the period before and after the introduction of the
pneumococcal vaccine. We retrospectively analyzed a large cohort of patients admitted to
the four main public hospitals in Singapore with S. pneumoniae infection between 1997
and 2013. A total of 889 (64% of all isolates identified in the clinical laboratories) cases
were included in the analysis; 561 (63.1%) were adult (�16 years) cases with a median
age of 62 years and 328 (36.9%) were paediatric cases with a median age of 3 years. Bac-
teraemic pneumonia was the most common syndrome in both groups (69.3% vs. 44.2%),
followed by primary bacteraemia without pneumonia (14.3% vs. 13.4%), meningitis (6.4%
vs. 7.6%) and non-bacteraemic pneumonia (5.2% vs. 21%). The major serotypes in adults
were 3, 4, 6B, 14, 19F and 23F whereas in children they were 14, 6B and 19F, accounting
both for nearly half of pneumococcal disease cases. No particular serotype was associ-
ated with mortality or severity of the pneumococcal disease. Overall mortality rate was
18.5% in adults and 3% in children. Risk factors for mortality included acute cardiac events
in adults, meningitis in children and critical illness and bilateral pulmonary infiltrates in both
adults and children. Penicillin resistance was not associated with increased mortality. Our
results agree with global reports that the course of pneumococcal disease and its clinical
outcome were more severe in adults than in children. The main serotypes causing invasive
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disease were mostly covered by the vaccines in use. The high mortality rates reflect an
urgent need to increase vaccination coverage in both adults and children to tackle this vac-
cine-preventable infection.
Introduction
Streptococcus pneumoniae (pneumococcus) is one of the most common causes of morbidity
and mortality among children and adults worldwide, with an estimated 800,000 annual deaths
in children under 5 years of age globally [1]. Though colonization with pneumococci is mostly
asymptomatic, it can cause a range of diseases from mild localized infections such as acute oti-
tis media and sinusitis, to more severe infections such as pneumonia, bacteraemia and menin-
gitis [2].
Pneumonia with empyema and/or bacteraemia, febrile bacteraemia and meningitis are the
most common manifestations of invasive pneumococcal disease (IPD). While children under
the age of 2 years and adults over 65 years of age are reportedly at higher risk of IPD [3],
comorbidities such as diabetes mellitus, chronic heart and lung conditions, and immune defi-
ciencies also increase the risk of developing pneumococcal disease [3–5].
The ability of pneumococcus to cause disease is directly related to the production of poly-
saccharide capsule, a structure that provides resistance to phagocytosis and allows host
immune evasion by the bacteria [6]. To date, 98 antigenically distinct capsules have been
reported in pneumococcus, corresponding to 98 distinct serotypes [7]. Despite the large vari-
ety of serotypes, only small fractions have been associated with increased invasive potential
and mortality [4]. As vaccine responses are highly serotype-dependent, pneumococcal vac-
cines were designed such that they consist of purified capsular polysaccharides from serotypes
associated with IPD [5].
In Singapore, the 7-valent pneumococcal polysaccharide conjugate vaccine (PCV7) has
been available on demand since 2005, and was added to the National Childhood Immuniza-
tion Program (NCIP) in October 2009, but later replaced by the PCV13 in December 2011 [8].
Currently, the 10-valent Paediatric PHiD-CV, PCV13, and the 23-valent pneumococcal poly-
saccharide vaccine (PPV23) are the three pneumococcal vaccines available in Singapore [9,10].
The recommended pneumococcal vaccine immunization strategy is to administer PCV13 or
PHiD-CV to all infants at three and five months of age, with a booster at 12 months. For
adults, the recommendation is to use a single dose of PPV23 for elderly and people at higher
risk of acquiring pneumococcal disease and add PCV13 at a later stage to enhance the vaccine
protection [10]. Although PCV and PPV23 vaccines are recommended by the NCIP and the
National Adult Immunization Program (NAIS), neither are provided free and families pay
either out of pocket, through insurance or through their medical savings accounts. As it is offi-
cially recommended, providers are more likely to encourage families to pay for the vaccina-
tion, the uptake is likely to be much higher if the vaccines were provided for free [11].
However, despite inclusion of the PCVs in the NCIP in Singapore, the incidence of IPD in
all age groups remains high. Although, decrease in IPD rates in children was reported a year
after PCV7 implementation [11], it is yet not clear whether serotype distribution and pneumo-
coccal disease severity and outcome changed over time in Singapore and what has been the
impact on non-vaccine pneumococcal serotypes. This information will be important in the
evaluation of current vaccine strategies and will provide the basis for future vaccination
policies.
Pneumococcal infection in adults and children in Singapore
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Here, we present a review encompassing changes in risk factors and outcome for pneumo-
coccal infections in Singaporean adults and children spanning over 16 years.
Methods
Study design
We retrospectively collected clinical data on patients admitted to hospital with laboratory
confirmed pneumococcal infection between January 1997 and December 2013. We reviewed
records of 1,389 non-duplicate patients from four major public hospitals in Singapore: Tan
Tock Seng Hospital, KK Women’s and Children’s Hospital, Singapore General Hospital and
National University Hospital. Clinical data were collected from case notes and electronic med-
ical records. Ethics for the study was approved by the Group Domain Specific Review Board
(reference number 2013/01036).
Definitions and exclusion criteria
IPD was defined as isolation of S. pneumoniae from a sterile site: blood, cerebrospinal fluid
(CSF), pleural and peritoneal fluid, and others such as bone or joints. Non-invasive pneumo-
coccal disease (non-IPD) was described when pneumococcus was recovered from a non-sterile
clinical specimen such as sputum, tracheal/bronchial aspirates, and ear secretions.
Clinical syndromes were classified as follows: a) Bacteraemia: presence of a positive pneu-
mococcal blood culture and no other documented site of infection; b) Bacteraemic pneumo-
nia: lung infection confirmed by radiologic evidence of new-onset pulmonary infiltrates or
consolidation, and a positive pneumococcal blood culture; c) Meningitis: isolation of pneumo-
coccus from CSF, or positive pneumococcal-specific latex agglutination test on CSF sample,
with or without concomitant bacteraemia; d) Other invasive infections: presence of a positive
pneumococcal culture from a sterile site, excluding blood and CSF; e) Non-bacteraemic pneu-
monia: lung infection confirmed by radiological investigation and isolation of pneumococcus
from sputum (the majority of the samples from children were obtained from suction or possi-
ble nebulised specimens), lung tissue or pleural cavity; f) Non-invasive infections: isolation of
pneumococcus from a normally non-sterile site.
Immunosuppression was defined as presence of chronic renal failure, nephrotic syndrome,
malignancy, solid organ transplant, or iatrogenic immunosuppression (>20mg prednisolone
for>2 weeks). Critical illness was defined as having a Pitt bacteraemia score of>4 points
based on values assessed 48 hours before or on the day of first positive S. pneumoniae culture
[12]. Acute cardiac event during admission was defined as presenting new or worsening heart
failure, arrhythmias or myocardial infarction. Adults were defined as 16 years old and older,
and children were defined as under 16 years old. The analysis was limited to patients with labo-
ratory confirmed pneumococcal disease.
Information on pneumococcal isolates
Serotype data were available for 842 pneumococcal isolates linked to clinical cases. Serotype
information was acquired from whole genome sequences (Jauneikaite et al, unpublished).
Antibiotic susceptibility to benzylpenicillin, ceftriaxone, erythromycin and tetracycline was
tested for 482 pneumococcal isolates using E-test strips (bioMe´rieux, France). Isolates were
defined as susceptible, intermediate susceptibility, or non-susceptible according to the inter-
pretive standards of the Clinical and Laboratory Standards Institute [13]. In this study, isolates
with intermediate susceptibility and full resistance to the named antibiotics were all grouped
as non-susceptible isolates. Multi-drug resistance was reported if pneumococcal isolate was
Pneumococcal infection in adults and children in Singapore
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non-susceptible to at least one agent in three or more antimicrobial categories. Concordant
antibiotic therapy was reported if treatment with one or more antibiotics to which a pneumo-
coccal isolate was susceptible was given to patient within the first 48 hours of pneumococcal
isolation. To further study temporal changes in serotypes and antibiotic resistance, the study
was divided in three periods: period 1, years 1998–2004, pre-introduction of PCV7; and period
2, after PCV introduction. Period 2 was further divided in early period (2005–2009), where
PCV7 was introduced in Singapore but mainly used in the private sector; and late period
(2010–2013), after Singapore inclusion of PCV7 and later PCV13 in the NCIP.
Statistical analysis
Statistical analyses were done using STATA v.11 (Stata Corporation, USA). Categorical find-
ings were summarized in frequency tables. Continuous variables were expressed as means and
standard deviations (SD) or as medians and interquartile ranges (IQR). Chi-square test (two-
tailed) or Fisher’s exact test was used to determine the association analysis for categorical data.
For continuous data, ANOVA test was used to determine statistical differences in median and
t-test to determine differences in means among groups. The association between each popula-
tion and covariates was assessed by univariate and multivariate logistic regression models and
was expressed as an odds ratio with a 95% confidence interval (95% CI). Model covariates
included those factors that were found to be significant by univariate analysis and those that
had previously been found in the literature to affect the disease severity or mortality [14,15],
and were selected based on a model fit aided by Akaike information criterion values [16]. A
two-tailed p-value<0.05 was considered statistically significant.
Results
Patient population characteristics
Eight hundred eighty-nine (64%) of 1,389 cases were included in the analysis (S1 Fig). Five
hundred sixty-one (63.1%) patients were adults and 328 (36.9%) were children (Table 1).
Median (IQR) age was 62 (49–72) years in adults and 3 (1–5) years in children. Among them,
241 (27.1%) were aged�65 years and 240 (27%) <5 years. Fifty-four (16.5%) children and 22
(3.9%) adults in our cohort had received at least one dose of the appropriate pneumococcal
vaccination at the time; of these 57.9% were under 5 years old (n = 44) and 10.5% of the adults
were�65 years (n = 8). Of the vaccinated adults, 9.1% received PCV7 (n = 2), 68.2% received
PPV23 (n = 15) and for 22.7% the information on vaccine type was not available (n = 5). In the
children group, 68.5% received PCV7 (n = 37), 24.1% received PCV13 (n = 13), 5.5% received
PPV23 (n = 3) and 1.9% we were unable to obtain the type of vaccine (n = 1).
The overall ethnic distribution was: Chinese 561 (63.1%), Malays 159 (17.9%), Indian 122
(13.7%), others 47 (5.3%) and broadly reflected the national ethnic distribution (Singapore
Department of Statistics, 2016).
Clinical syndromes and outcome
Bacteraemic pneumonia was the most common syndrome in adults (69.3%) and children
(44.2%), followed by bacteraemia (14.3% vs. 13.4%), meningitis (6.4% vs. 7.6%) and non-bac-
teraemic pneumonia (5.2% vs. 21.0%) (Fig 1). Viral co-infection was more common in chil-
dren group, especially in infants when compared to other children groups (Table 2). However,
this did not result in infants requiring more invasive interventions compared to other older
children or adult groups (Table 2). Seizures also were more commonly observed in infant
group than any other group (Table 2). There were no significant differences observed between
Pneumococcal infection in adults and children in Singapore
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the two adult age groups when interventions or outcomes were compared. Overall, mortality
rates during hospitalization were significantly higher in adults when compared to children
(18.5% vs. 3.1%; P =<0.001) (Table 2). Among the adults who died, 62 (59.6%) were�65
years old (Table 3) and 50% of the adults below 65 years who died, had comorbidities (S1
Table). The case fatality rate was highest for pneumonia in adults (24.2%) and for meningitis
in children (20%), and for infant group there were no deaths reported where data was available
(Table 4).
Risk factors for pneumococcal disease mortality
In adult patients, multivariate logistic regression showed that age�65 years (OR 2.5, 95% CI
1.4–4.6; P = 0.002), dementia (OR 6.8, 95% CI 2.0–23.3; P = 0.002), acute cardiac events (OR
Table 1. Baseline characteristics of patients with pneumococcal disease by age group.
Total
(N = 889)
Infants <12mo
(n = 38)
1-2yrs
(n = 95)
3–4 yrs
(n = 107)
5-15yrs
(n = 88)
16-64yrs
(n = 320)
�65yrs
(n = 241)
Age-median (IQR), years 45 (4–66) 0 (0–0) 2 (1–2) 4 (3–4) 6 (5–8.5) 51 (37–59) 74 (69–80)
Gender, n (%)
Male 593 (66.7) 23 (60.5) 54 (56.8) 67 (62.6) 54 (61.4) 225 (70.3) 170 (70.5)
Female 296 (33.3) 15 (39.5) 41 (43.2) 40 (37.4) 34 (38.6) 95 (29.7) 71 (29.5)
Comorbidities, n (%)
At least 1 significant comorbidity 437 (49.2) 3 (7.9) 14 (14.7) 23 (21.5) 21 (23.9) 196 (61.3) 180 (74.7)
Diabetes Mellitus 120 (13.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 56 (17.5) 64 (26.6)
Chronic Heart Disease 107 (12.0) 2 (5.3) 1 (1.1) 1 (0.9) 0 (0.0) 31 (9.7) 72 (29.9)
Immunocompromised 114 (12.8) 0 (0.0) 1 (1.05) 9 (8.4) 8 (9.1) 43 (13.4) 53 (22.0)
Smoking 95 (10.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 61 (19.1) 34 (14.1)
Asthma 73 (8.2) 1 (2.6) 9 (9.5) 10 (9.4) 9 (10.2) 28 (8.8) 16 (6.6)
COPD 37 (4.2) 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.3) 32 (13.3)
Alcoholism 33 (3.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25 (7.8) 8 (3.3)
Renal Insufficiency 30 (3.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 11 (3.4) 19 (7.9)
Chronic Liver Disease 23 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 11 (3.4) 11 (4.6)
HIV 22 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 19 (5.9) 2 (0.8)
Dementia 14 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 14 (5.8)
Living condition
At home 754 (84.8) 37 (97.4) 95 (100) 107 (100) 88 (100) 241 (75.3) 186 (77.2)
In nursing home 15 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.3) 11 (4.6)
Others 20 (2.2) 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 17 (5.3) 2 (0.8)
Unknown 100 (11.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 58 (18.1) 42 (17.4)
Previous S. pneumoniae vaccination
No 634 (71.3) 5 (13.2) 19 (20.0) 20 (18.7) 10 (11.3) 14 (4.4) 8 (3.3)
Yes 76 (8.6) 33 (86.8) 76 (80.0) 85 (79.4) 76 (86.4) 213 (66.6) 151 (62.7)
Unknown 179 (20.1) 0 (0.0) 0 (0.0) 2 (1.9) 2 (2.3) 93 (29.0) 82 (34.0)
Radiologicala
Bilateral Infiltrates 160 (20.4) 4 (16) 9 (11.3) 16 (17.4) 13 (17.6) 58 (20) 60 (27)
Pleural effusion 249 (31.8) 2 (8.0) 23 (28.8) 33 (35.9) 28 (37.8) 86 (29.7) 77 (34.7)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: IQR, interquartile range; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus.
aClosest chest X-ray (CXR) to the positive S. pneumoniae culture, available for 25 infants, 80 children from 1-2yrs, 92 from 3-4yrs, 74 from 5-15yrs, and 290 adults from
16-64yrs and 222�65yrs.
https://doi.org/10.1371/journal.pone.0220951.t001
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2.4, 95% CI 1.2–4.7; P = 0.013), critical illness (OR 14.2, 95% CI 6.7–30.2; P = <0.001) and
multilobar pulmonary involvement (OR 3.0, 95% CI 1.7–5.3; P =<0.001) were significantly
associated with death (Table 3). In children, multivariate analysis revealed that the risk for
death was higher for patients with meningitis (OR 17.2, 95% CI 1.6–187.5; P = 0.019), critical
illness (OR 24.0, 95% CI 3.4–171.5; P = 0.002), and bilateral infiltrates (OR 11.9, 95% CI 11.2–
117.5; P = 0.034) (Table 4). Inferences were not altered in the sensitivity analysis where only
patients with IPD were included to address bias (S2 and S3 Tables).
Pneumococcal serotype and antimicrobial susceptibility changes in relation to disease
syndrome and time period. Serotypes 3, 23F, 14, 6B, 19F and 4 were most commonly identi-
fied in adult pneumococcal disease, and 14, 6B and 19F were most common in children (Fig
2). Serotype 6B was most prevalent in adults with bacteraemia without focus (17%) and one of
the most prevalent in meningitis along with serotypes 1 and 23F (11%). Serotype 14 was the
most prevalent in children with meningitis, bacteraemia and bacteraemic pneumonia followed
by serotype 6B (S4 and S5 Tables). Serotypes 3, 23F, 6B, 14 and 19F were identified in ~50% of
the adult fatalities, with serotype 3 identified in 24% alone (15 out of 63 cases). In children,
Fig 1. Distribution of pneumococcal disease syndromes by age group.
https://doi.org/10.1371/journal.pone.0220951.g001
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Table 2. Disease outcome during hospitalization and at discharge by age group.
Total
(N = 889)
Infants <12mo
(n = 38)
1-2yrs
(n = 95)
3–4 yrs
(n = 107)
5-15yrs
(n = 88)
16-64yrs
(n = 320)
�65yrs
(n = 241)
P-value
Length of stay in hospital, days, median (IQR) 8 (4–15) 6 (4–17) 6 (4–12) 8.5 (6–15) 10 (5–16) 7.5 (4–15) 8 (4–15) 0.3601
Viral Co-infection 44 (5.0) 9 (23.7) 11 (11.7) 8 (7.5) 6 (6.8) 10 (3.1) 0 (0.0) <0.0012
Required ICU, n (%) 194 (21.8) 6 (15.8) 16 (16.8) 26 (24.3) 23 (26.1) 79 (24.7) 44 (18.3) 0.9232
Length of stay in ICU, days, median (IQR) 3 (2–8) 3.5 (2–6) 2 (1–4) 2 (1–8) 5 (3–13) 3 (2–6) 3 (1.5–7) 0.1511
Critical illness (PBS>4) 72 (8.1) 2 (5.3) 5 (5.3) 8 (7.5) 6 (6.8) 30 (9.4) 21 (8.7) 0.7752
Invasive interventions
Supplemental oxygen 383 (43.1) 8 (21.6) 29 (30.5) 41 (38.3) 37 (42.0) 128 (40.0) 140 (58.1) <0.0012
Non-invasive mechanical ventilation 79 (8.9) 2 (5.4) 11 (11.6) 17 (15.9) 16 (18.2) 13 (4.1) 20 (8.3) <0.0012
Invasive mechanical ventilation 153 (17.2) 5 (13.5) 14 (14.8) 13 (12.2) 14 (15.9) 67 (21.0) 40 (16.6) 0.3092
Renal replacement therapy 26 (2.9) 0 (0.0) 1 (1.1) 2 (1.9) 3 (3.4) 12 (3.8) 8 (3.3) 0.5972
Inotropes/vasopressors 102 (11.5) 1 (2.7) 2 (2.1) 9 (8.4) 10 (11.4) 42 (13.1) 38 (15.8) 0.0042
Blood transfusion or products 68 (7.7) 0 (0.0) 8 (8.4) 13 (12.2) 13 (14.8) 19 (6.0) 15 (6.2) 0.0133
Surgical procedures 238 (26.8) 6 (16.2) 29 (30.5) 42 (39.3) 41 (46.6) 71 (22.2) 49 (20.3) <0.0012
Clinical outcome
Non-pneumococcal nosocomial complication 86 (9.7) 2 (5.3) 9 (9.5) 13 (12.2) 12 (13.6) 28 (8.8) 22 (9.1) 0.5092
ARDS 25 (2.8) 0 (0.0) 0 (0.0) 3 (2.8) 5 (5.7) 10 (3.1) 7 (2.9) 0.2563
Pneumothorax 23 (2.6) 1 (2.6) 2 (2.1) 6 (5.6) 5 (5.7) 5 (1.6) 4 (1.7) 0.0803
Seizures 35 (3.9) 5 (13.2) 6 (6.3) 8 (7.5) 0 (0.0) 11 (3.4) 5 (2.1) 0.0023
Stroke 7 (0.8) 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 2 (0.6) 4 (1.7) 0.7213
Acute cardiac events 84 (9.5) 1 (2.6) 1 (1.1) 2 (1.9) 2 (2.3) 31 (9.70 47 (19.5) <0.0013
Coagulopathy or DIC 52 (5.9) 0 (0.0) 4 (4.2) 5 (4.7) 5 (5.7) 22 (6.9) 16 (6.6) 0.6203
Rhabdomyolisis 14 (1.6) 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 7 (2.2) 6 (2.5) 0.4543
Acute renal injury 148 (16.7) 0 (0.0) 3 (3.2) 4 (3.7) 7 (8.0) 71 (22.2) 63 (26.1) <0.0012
Gastrointestinal bleeding 10 (1.1) 0 (0.0) 0 (0.0) 2 (1.9) 0 (0.0) 6 (1.9) 2 (0.8) 0.5863
Hepatic dysfunction 45 (5.1) 0 (0.0) 1 (1.1) 2 (1.9) 4 (4.6) 19 (5.9) 19 (7.9) 0.0353
Hyperglycemia 22 (2.5) 0 (0.0) 0 (0.0) 2 (1.9) 1 (1.1) 12 (3.8) 7 (2.9) 0.3553
Hypoglycemia 14 (1.6) 0 (0.0) 1 (1.1) 1 (0.9) 0 (0.0) 7 (2.2) 5 (2.1) 0.8253
Discharge outcome
Alive without sequelae 676 (76.1) 35 (92.1) 87 (91.6) 95 (88.8) 78 (88.6) 235 (73.5) 146 (60.6)
Alive with sequelae 99 (11.1) 3 (7.9) 5 (5.2) 8 (7.5) 7 (8.0) 43 (13.4) 33 (13.7)
Dead 114 (12.8) 0 (0.0) 3 (3.2) 4 (3.7) 3 (3.4) 42 (13.1) 62 (25.7) <0.0012
Concordant therapya 247 (83.2) 5 (83.3) 11 (36.7) 17 (54.8) 16 (64.0) 116 (99.2) 82 (93.2) <0.0012
Time to antibiotics, days, median (IQR)b 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) <0.6651
Time to death from admission, days, median (IQR) 3 (1–10) NA 1 (0–4) 0 (0–0.5) 16 (5–42) 3 (1–9) 3 (1–10) 0.2651
Data are presented as No. (%) unless otherwise specified.
Abbreviations: IQR, interquartile range; ICU, intensive care unit; PBS, Pitt bacteraemia score; ARDS, acute respiratory distress syndrome; DIC, disseminated
intravascular coagulation; NA, non-applicable.
1 ANOVA test;
2Chi-squared test;
3Fisher’s exact test.
a Prescribed medication and MIC available for 205 adults and 92 children.
b Prescribed medication available for 485 adults and 285 children.
https://doi.org/10.1371/journal.pone.0220951.t002
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Table 3. Factors associated with disease outcome at discharge in Adults with S. pneumoniae infection.
Cured (%) Discharged w/ sequelae (%) Death (%) OR, univariate (95% CI) P-value OR, multivariate (95% CI) P-value
n = 381 n = 76 n = 104
Gender�
Male 260 (65.8) 56 (14.2) 79 (20.0) 1
Female 121 (72.9) 20 (12.0) 25 (15.1) 0.7 (0.4–1.2) 0.171
Age group, years�
16–64 235 (73.4) 43 (13.4) 42 (13.1) 1
�65 146 (60.6) 33 (13.7) 62 (25.7) 2.3 (1.5–3.5) <0.001 2.5 (1.4–4.6) 0.002
Type of PD
Bacteremic pneumonia 264 (67.9) 47 (12.1) 78 (20.0) 1
Bacteremia 61 (76.3) 6 (7.5) 13 (16.2) 0.8 (0.4–1.5) 0.435
Meningitis 23 (63.9) 7 (19.4) 6 (16.7) 0.8 (0.3–2.0) 0.626
Others IPD 15 (71.4) 6 (28.6) 0 (0.0)
Pneumonia 13 (44.8) 9 (31.0) 7 (24.2) 1.3 (0.5–3.1) 0.599
Others non IPD 5 (83.3) 1 (16.7) 0 (0.0)
Comorbidities
Any� 259 (68.9) 52 (13.8) 65 (17.3) 0.8 (0.5–1.2) 0.278
CHD 74 (71.9) 13 (12.6) 16 (15.5) 0.7 (0.4–1.4) 0.386
Asthma 35 (79.5) 5 (11.4) 4 (9.1) 0.4 (0.1–1.2) 0.103
COPD� 29 (80.5) 5 (13.9) 2 (5.6) 0.2 (0.1–1.0) 0.055 0.1 (0.0–0.8) 0.023
Renal Insufficiency 19 (63.3) 3 (10.0) 8 (26.7) 1.6 (0.7–3.8) 0.243
Chronic liver disease 11 (50.0) 5 (22.7) 6 (27.3) 1.7 (0.6–4.4) 0.287
Immunocompromised 63 (65.6) 13 (13.6) 20 (20.8) 1.2 (0.7–2.1) 0.525
HIV 17 (80.9) 3 (14.3) 1 (4.8) 0.2 (0.1–1.6) 0.132
Diabetes mellitus 85 (70.8) 14 (11.7) 21 (17.5) 0.9 (0.5–1.6) 0.741
Dementia� 5 (35.7) 0 (0.0) 9 (64.3) 8.5 (2.8–26.1) <0.001 4.2 (1.2–14.8) 0.024
Alcohol consumption 19 (57.6) 6 (18.2) 8 (24.2) 1.4 (0.6–3.2) 0.39
Smoking 65 (68.4) 17 (17.9) 13 (13.7) 0.7 (0.3–1.2) 0.181
Clinical
Fever� 295 (75.1) 41 (10.4) 57 (14.5) 0.4 (0.3–0.7) <0.001 0.5 (0.3–0.8) 0.009
Chest pain� 115 (79.9) 20 (13.9) 9 (6.2) 0.2 (0.1–0.5) <0.001 0.3 (0.1–0.7) 0.006
Acute cardiac events� 38 (48.7) 14 (18.0) 26 (33.3) 2.6 (1.5–4.4) <0.001 1.9 (0.9–3.9) 0.064
Critical illness (PBS>4)� 8 (15.7) 6 (11.8) 37 (72.5) 17.5 (9.0–34.0) <0.001 17.8 (8.0–39.6) <0.001
Bilateral Infiltratesa� 63 (53.4) 13 (11.0) 42 (35.6) 3.4 (2.1–5.5) <0.001 2.9 (1.6–5.1) <0.001
Pleural effusiona� 135 (59.7) 44 (19.5) 47 (20.8) 1.7 (1.1–2.6) 0.028
Treatment
Discordant therapy 5 (71.4) 2 (28.6) 0 (0.0)
Penicillin resistanceb 66 (60) 17 (15.5) 27 (24.5) 1.6 (0.9–2.8) 0.107
MDRb 11 (55.0) 5 (25.0) 4 (20.0) 1.1 (0.3–3.4) 0.89
Data are presented as No. (%) unless otherwise specified.
Abbreviations: PD, pneumococcal disease; IPD, invasive pneumococcal disease; CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; HIV,
human immunodeficiency virus; MDR, multidrug resistance.
a Chest X-ray available for 512 adults during admission.
b MIC available for 324 adults.
�Variables tested on multivariate analysis.
https://doi.org/10.1371/journal.pone.0220951.t003
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serotypes 19F and 6B were identified in 60% of the deaths, with the highest case fatality rate for
serotype 19F (4 deaths for 56 cases).
We further compared the changes in composition of serotypes between the three study
periods. There was a significant difference in serotype composition between period 1 and both
the early and late PCV introduction periods in both groups (S6 and S7 Tables). Serotype 19A
Table 4. Factors associated with disease outcome at discharge in children with S. pneumoniae infection.
Cured (%) Discharged w/ sequelae (%) n = 22 Death (%) OR, univariate (95% CI) P-value OR, multivariate (95% CI) P-value
n = 295 n = 10
Gender�
Male 185 (93.4) 10 (5.1) 3 (1.5) 1
Female 110 (84.6) 13 (10) 7 (5.4) 3.7 (0.9–14.5) 0.063
Age group�
Infants <12mo 35 (92.1) 3 (7.9) 0 (0.0)
1-2yrs 87 (91.6) 5 (5.3) 3 (3.2) 0.8 (0.2–3.9) 0.822
3-4yrs 95 (88.8) 8 (7.5) 4 (3.7) 1
5-15yrs 78 (88.6) 7 (8.0) 3 (3.4) 0.9 (0.2–4.2) 0.902
Type of PD
Bacteremic pneumonia 134 (92.4) 7 (4.8) 4 (2.8) 1
Bacteremia 43 (97.7) 1 (2.3) 0 (0)
Meningitis� 13 (52) 7 (28) 5 (20) 8.8 (2.2–35.6) 0.002 17.2 (1.6–187.5) 0.019
Others IPD 16 (94.1) 1 (5.9) 0 (0)
Pneumonia 63 (91.3) 5 (7.3) 1 (2.5) 0.5 (0.1–4.7) 0.56
Others non IPD 26 (92.9) 2 (7.1) 0 (0)
Comorbidities
Any� 50 (81.9) 7 (11.5) 4 (6.6) 3.1 (0.8–11.2) 0.092 6.1 (0.8–46.6) 0.083
CHD 3 (75) 1 (25) 0 (0)
Asthma 26 (89.7) 3 (10.3) 0 (0)
Immunocompromised 18 (100) 0 (0) 0 (0)
HIV 0 (0) 0 (0) 1 (100)
Chronic liver disease 0 (0) 0 (0) 1 (100)
Clinical
Fever 272 (91.0) 19 (6.3) 9 (3.0) 0.8 (0.1–6.8) 0.867
Chest pain 20 (100) 0 (0) 0 (0)
Acute cardiac events� 2 (33.3) 1 (16.7) 3 (50) 45.0 (7.7–263.4) <0.001
Critical illness (PBS>4)� 7 (33.3) 7 (33.3) 7 (33.3) 50.7 (11.8–217.0) <0.001 24.0 (3.4–171.5) 0.002
Bilateral Infiltratesa� 32 (76.2) 4 (9.5) 6 (14.3) 9.4 (2.5–34.9) 0.001 11.9 (1.2–117.5) 0.034
Pleural effusiona 93 (87.7) 9 (8.5) 4 (3.8) 0.5(0.1–2.5) 0.424
Treatment
Discordant therapy 43 (100) 0 (0) 0 (0)
Penicillin resistanceb 100 (91.8) 7 (6.4) 2 (1.8) 0.5 (0.0–6.0) 0.602
MDRb 46 (86.8) 6 (11.3) 1 (1.9) 0.9 (0.1–10.1) 0.928
Data are presented as No. (%) unless otherwise specified.
Abbreviations: PD, pneumococcal disease; IPD, invasive pneumococcal disease; CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; HIV,
human immunodeficiency virus; MDR, multidrug resistance.
a Chest X-ray available for 271 children during admission.
b MIC available for 148 children.
�Variables tested on multivariate analysis.
https://doi.org/10.1371/journal.pone.0220951.t004
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Fig 2. Disease outcome at hospital discharge by age and serotype for patients with pneumococcal disease. Number
of reported cases where the outcome and the pneumococcal serotype were known: (A) overall cases in the study; (B)
adult only cases (>16 years old) and (C) children only cases (<16 years old).
https://doi.org/10.1371/journal.pone.0220951.g002
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increased by more than 5-fold in both groups from period 1 to period 2 (1.6% to 5.6% in adults
and from 4.5% to 20.8% in children).
Data on antibiotic susceptibility were available for 472 pneumococcal isolates (Table 5).
The prevalence of antimicrobial resistance was higher in pneumococcal isolates from children
than adults. Resistance to penicillin was reported in 79% of children and 35.4% of adult cases
(P =<0.001). Pneumococcal isolates from children were more likely to be non-susceptible to
multiple antibiotics when compared to isolates from adults (51.4% vs. 10.2%, respectively; P =
<0.001). There was not significant difference in antibiotic susceptibility between the time peri-
ods probably due to the small numbers of antibiotic susceptibility tests available for isolates
from the first period.
Among the 110 adult isolates non-susceptible to penicillin, 21 (19%) were of serotype 23F.
This serotype also accounted for the higher number of tetracycline resistance (26%). Serotype
19F was frequently non-susceptible to penicillin (16 isolates (84%)), tetracycline (5 isolates
(100%)) and erythromycin (3 isolates (75%)).
Overall, infections caused by the serotypes included in PCV7 accounted for 37% of the
adult IPD cases and 67% of children’ IPD cases. Pneumococcal disease caused by the addi-
tional six serotypes included in PCV13 represented a further 25% of the adults and 21% of
children’s cases. Also, 8% of adults and 1% of children pneumococcal disease cases were attrib-
uted to the additional serotypes included in PPV23, while 30% and 11% corresponded to
serotypes currently not included in any of the pneumococcal vaccines in adults and children,
respectively.
Discussion
This is the first large-scale retrospective study investigating differences in pneumococcal dis-
ease and clinical outcomes between adult and paediatric populations in Singapore. Data col-
lected between 1997 and 2013 showed that mortality due to pneumococcal disease was high,
Table 5. Antibiotic susceptibility results for S. pneumoniae by age group.
Adult� 16yrs Children <16yrs P-
value1
Susceptible Non-
susceptible
Non-susceptible serotypes n(%)2 Susceptible Non-
susceptible
Non-susceptible serotypes n(%)2
Penicillin 201/311
(64.6)
110/311
(35.4)
1: 1(17); 14: 18(72); 15A: 4 (80); 19A: 18
(56); 19F: 16(84); 23A: 6(67); 23F: 21(68);
3: 4(13); 35B: 1(100); 38: 1(50); 4: 1(5); 6A:
2(50); 6B: 12(50); 6C: 1(11); 8: 2(9); 9A: 2
(100)
29/138
(21.0)
109/138
(79.0)
11D: 1(100); 14: 19(59); 15A: 1(100);
19A: 23(92); 19F: 27(96); 20: 1(100);
23A: 1(100); 23F: 14(82); 3: 1(40); 4: 1
(100); 6A: 3(37.5); 6B: 14 (88)
<0.001
Ceftriaxone 261/269
(97.0)
8/269 (3.0) 19A: 1(6.3); 19F: 3(17); 23F: 2(7); 6A: 1
(25); 8: 1(6.3)
126/137
(92.0)
11/137 (8.0) 14: 1(4); 19A: 4(14); 19F: 3(10); 6B: 3
(16)
0.023
Tetracycline 35/78 (44.9) 43/78 (55.1) 12F: 2(100); 14: 2(40); 15A: 1(100); 18B/
C: 1(100); 18F: 1(100); 19A: 2(40); 19F: 5
(100); 20: 1(50); 23A: 1(25); 23F: 11(85); 3:
4(40); 39: 1(100); 4: 3(100); 6A: 1(100);
6B: 3(43); 6C: 1(100); 7F: 1(50); 8: 2(33)
39/104
(37.5)
65/104
(62.5)
14: 9(45); 15A: 2(100); 19A: 17(65);
19F: 21(84); 20: 1(100); 23F: 9(69);
6B: 6(55)
0.316
Erythromycin 38/64 (59.4) 26/64 (40.6) 14: 2(100); 15A: 1(100); 18F: 1(100); 19A:
1(50); 19F: 3(75); 23A: 1(25); 23F: 9(75);
3: 2(22); 4: 1(33); 6A: 1(100); 6B: 2(40);
6C: 1(100); 8: 1(20)
15/89 (16.9) 74/89 (83.2) 14: 15(83); 15A: 1(100); 19A: 20(91);
19F: 22(92); 20: 1(100); 23F: 9(75); 3:
1(50); 6A: 1(25); 6B: 4(80)
<0.001
Data are presented as No. (%) unless otherwise specified.
1Chi-squared test
2Proportion of resistant isolates per total isolates of a given serotype. Serotypes with more than 50% of isolates resistant are shown in bold.
https://doi.org/10.1371/journal.pone.0220951.t005
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with up to 19% case fatality in adults and 3% in children. Bacteraemic pneumonia was the
most frequent clinical pneumococcal disease syndrome present in hospitalized patients. Over-
all 63% of pneumococcal isolates from adults and 88% isolates from children were serotypes
included in PCV13, however, the vaccination rates in studied populations were very low.
Approximately, 30% of serotypes identified in the study as causing disease were not covered in
any licensed vaccine.
We found that presenting syndromes such as critical illness, bilateral infiltrates on chest
imaging or dementia in adults and meningitis in children, were independent risk factors sig-
nificantly associated with mortality. Critical illness was the most important risk factor for
death in both groups, which is in agreement with other reported studies [15]. We did not find
immunosuppression, especially HIV infection, significantly associated with death as previously
shown in other literature [15], most probably due to the low HIV infection prevalence in this
cohort, although some cases of primary bacteraemia due to the pneumococcus may have been
in undiagnosed HIV positive individuals. Elderly patients presented a higher risk for death
than the younger adults, but no differences were found among children groups. Interestingly,
the mortality rates of severe pneumococcal cases were independent of the concordance of ther-
apy initiated or the pneumococcal isolate’s antibiotic susceptibility.
The introduction of conjugated pneumococcal vaccines in children has led to a significant
decline in incidence of IPD in all age groups, most likely due to herd effect from immunizing
infants, reducing nasopharyngeal colonization and transmission to other children and adults
in other countries [17,18] but this has not been the case in Singapore to our knowledge as the
majority of the cases described in this study were not vaccinated. Even though PCV7 for chil-
dren was introduced to the national immunization program in Singapore in 2009 and has also
been recommended for adults with comorbidities and the elderly (>65 years and older), only a
small proportion of them were vaccinated. Since the introduction of pneumococcal vaccines
to the NCIP, the vaccination uptake has been slowly increasing from 21.6% in 2009 to 60% in
2012 [19] reaching coverage of two doses of PCV in Singapore by the age 1 year of 79.6%, and
coverage of the booster dose by age 2 years of 58.9% in 2013 [11]. However, the costs of vacci-
nation are still to be covered by the patient which could in partly explain the low levels of vacci-
nation. This and high adult mortality rate in our study reflect an urgent need to address this
issue and rethink the current pneumococcal vaccination strategies in the country. In our
study, serotype 19A increased dramatically in both children and adults in the post-PCV7
period. This is a great concern because we also found a high proportion of penicillin-non-sus-
ceptible strains among this serotype. Serotype replacement in IPD was observed after wide-
spread use of PCV7 and this replacement has been dominated by penicillin non-susceptible
serotype, 19A in several countries [20,21], hence, it is not surprising that the rise has been seen
in Singapore too, especially when vaccination uptakes rates were fairly low. Although, this
serotype, is already included in PCV13, it should be closely monitored in the future as well as
any other non-vaccine serotypes.
Antibiotic resistance in S. pneumoniae has increased greatly worldwide over the last decade
[22–24]. In Singapore, the resistance rate of 62% for paediatric isolates was reported in 2004,
while 47.5% of adult isolates were non-susceptible in 2001 [22,25]. Here, we showed higher
resistance rates in disease-causing pneumococcal isolates with 79% of paediatric pneumococ-
cal isolates and 35.4% of adult isolates being non-susceptible to penicillin. This increase
seems to be serotype dependent, likely due to the emergence of widely drug non-susceptible
serotype 19A after the PCV7 introduction in Singapore. Likewise, erythromycin resistance has
increased substantially from previous reports, reaching 40.6% in adults and 83.2% in children,
probably correlated with an increase in macrolide consumption [26]. Children have been
reported as the major reservoir of S. pneumoniae and they are also more susceptible to
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pneumococcal disease caused by non-susceptible strains [27,28], potentially explaining why
children from our study were also more likely to be infected with pneumococcal strains non-
susceptible to at least one antibiotic. This could also be a result of the likelihood that children
in Singapore were more likely to be prescribed antibiotics than adults in our study.
However, despite this dramatic escalation, analyzing the impact of antimicrobial resistance
per se on clinical outcomes is difficult. MDR and penicillin resistance were not associated with
increased mortality among patients with pneumococcal disease in this study, where the vast
majority od isolates had a penicillin MIC below 4mg/dl. Previous studies have shown that anti-
microbial resistance to penicillin can be overcome with increasing doses of penicillin and thus
the growing threat of antibiotic resistance has not yet become clinically relevant in the man-
agement of pneumococcal pneumonia [15].
We also found that discordant antimicrobial regimens prescribed at admission for patients
with drug non-susceptible isolates was not significantly associated with a higher mortality rate.
This suggests that mortality in patients with pneumococcal disease could be related to other
host factors or pathogen virulence determinants rather than antibiotic sensitivity or early treat-
ment adequacy [29].
Overall mortality rate in this study was remarkably higher in the adults (18.5% vs. 3.1%,
P<0.001), similar to others [30–32]. Similar to prior smaller studies from Singapore, we
found that the main cause of death in adults was pneumonia and in children was meningitis
[25,33]. Surprisingly, the presence of meningitis was only significantly associated with death
in the paediatric population, but not in adults. This could have been related to the small
numbers of adult meningitis cases, probably underestimated in our study. The case fatality
rate was higher for vaccine serotypes 4, 3 and 6B in adults and 19F and 6B in children, in
agreement with previous reports from Belgium, the Netherlands and the US [34,35]. Half of
the fatal cases in the adults under 65 years old took place in patients without predisposing
underlying conditions, and therefore, without a recognized pneumococcal vaccine indica-
tion by current guidelines. The rates of vaccination in our cohort are so low that it is hard to
determine the impact on the elderly but the data on invasive disease suggests that the poten-
tial to have a marked impact is significant as this has been seen in other developed countries
[36]. Collectively, the higher mortality rates in the adult group strongly suggest the need to
strengthen vaccination efforts since vaccination of at-risk adults only and elderly may not
have the desired effect on mortality.
The other striking finding in our study was that 30% of isolates in adults including 18.6% of
fatal cases were serotypes not covered by any of the current vaccines. This has raised the con-
cern about the limitations of current vaccines and shows that serotype diversity can be seen
even in a population with a low vaccine uptake. This also furthers the need to improve on cur-
rent vaccines in terms of coverage.
Our study has several limitations. Firstly, the pneumococcal isolates were provided by the
laboratories depending on their availability, therefore, collected clinical data and serotype dis-
tributions do not represent the overall prevalence of pneumococcal disease in Singapore. Sec-
ondly, we were able to carry out phenotypic antibiotic susceptibility testing only on half the
available pneumococcal isolates included in the study, though isolates selected for testing were
randomly selected from range of patient ages to indicate the potential distribution of the anti-
biotic susceptible and non-susceptible isolates. Thirdly, although the syndrome classification
in our study required the microbiological results and its radiological and clinical support, a
misclassification might have occurred. Lastly, changes in guidelines for blood culture may
have occurred during the study period and some patients may have received antibiotic therapy
before obtaining blood samples and for these patients there is a possibility that pneumococcal
culture was not reported.
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In conclusion, host factors and responses to the illness play an important role in mortality,
and those are different in adults and children. Our results agree with global reports that the
course of pneumococcal disease and its clinical outcome were more severe in elderly adults
than in children. Although many of the main serotypes causing invasive disease were covered
by the vaccines in use, it is imperative to continue vigilance for emergence of novel serotypes
and development of vaccines with expanded coverage. The high mortality rates in this study
reflect an urgent need to increase vaccination coverage in both adults and children to tackle
this vaccine-preventable infection.
Supporting information
S1 Fig. Patient enrollment.
(DOCX)
S1 Table. Dead patients and comorbidities, by age group.
(DOCX)
S2 Table. Factors associated with disease outcome at discharge in adults with invasive S.
pneumoniae infection.
(DOCX)
S3 Table. Factors associated with disease outcome at discharge in children with invasive S.
pneumoniae infection.
(DOCX)
S4 Table. Distribution of pneumococcal serotypes and clinical presentation in adults.
(DOCX)
S5 Table. Distribution of pneumococcal serotypes and clinical presentation in children.
(DOCX)
S6 Table. Changes in proportion of adults PD serotypes from period 1 to period 2.
(DOCX)
S7 Table. Changes in proportion of children PD serotypes from period 1 to period 2.
(DOCX)
S1 Dataset.
(XLSX)
S1 Codebook.
(DOC)
Acknowledgments
We thank the patients, physicians and staff at the TTSH, KKH, SGH and NUH hospitals for
making this study possible and to E. Aruldoss for assisting us in data retrieval.
Author Contributions
Conceptualization: Rosario Martinez-Vega, Elita Jauneikaite, Koh Cheng Thoon, Oon Tek
Ng.
Data curation: Rosario Martinez-Vega, Hui Ying Chua, Amanda Huishi Chua.
Formal analysis: Rosario Martinez-Vega.
Pneumococcal infection in adults and children in Singapore
PLOS ONE | https://doi.org/10.1371/journal.pone.0220951 October 16, 2019 14 / 17
Funding acquisition: Oon Tek Ng.
Investigation: Rosario Martinez-Vega, Elita Jauneikaite, Hui Ying Chua.
Methodology: Rosario Martinez-Vega.
Project administration: Rosario Martinez-Vega, Oon Tek Ng.
Resources: Rosario Martinez-Vega, Koh Cheng Thoon, Amanda Huishi Chua, Oon Tek Ng.
Software: Rosario Martinez-Vega.
Supervision: Rosario Martinez-Vega, Oon Tek Ng.
Validation: Rosario Martinez-Vega, Oon Tek Ng.
Visualization: Rosario Martinez-Vega.
Writing – original draft: Rosario Martinez-Vega.
Writing – review & editing: Rosario Martinez-Vega, Elita Jauneikaite, Koh Cheng Thoon,
Wei Xin Khong, Ban Hock Tan, Jenny Low Guek Hong, Indumathi Venkatachalam, Paul
Anantharajah Tambyah, Martin L. Hibberd, Stuart C. Clarke, Oon Tek Ng.
References
1. Immunization, Vaccines and Biologicals Pneumococcal disease [Internet]. 2016 Jul pp. 1–2. http://
www.who.int/immunization/topics/pneumococcal_disease/en/#
2. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol. Microbiology
Society; 2000; 49: 1057–1067. https://doi.org/10.1099/0022-1317-49-12-1057 PMID: 11129716
3. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal con-
jugate vaccines. Clin Microbiol Rev. 2012; 25: 409–419. https://doi.org/10.1128/CMR.00018-12 PMID:
22763632
4. Jansen AGSC, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al. Inva-
sive pneumococcal disease among adults: associations among serotypes, disease characteristics, and
outcome. Clin Infect Dis. Oxford University Press; 2009; 49: e23–9. https://doi.org/10.1086/600045
PMID: 19522653
5. Bogaert D, Hermans PWM, Adrian PV, Ru¨mke HC, De Groot R. Pneumococcal vaccines: an update on
current strategies. Vaccine. 2004; 22: 2209–2220. https://doi.org/10.1016/j.vaccine.2003.11.038 PMID:
15149779
6. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits
complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun. 2010; 78:
704–715. https://doi.org/10.1128/IAI.00881-09 PMID: 19948837
7. Jauneikaite E, Tocheva AS, Jefferies JMC, Gladstone RA, Faust SN, Christodoulides M, et al. Current
methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods. 2015; 113: 41–49.
https://doi.org/10.1016/j.mimet.2015.03.006 PMID: 25819558
8. Health SMO. Epidemiological News Bulletin [Internet]. https://www.moh.gov.sg/content/dam/moh_
web/Publications/Epidemiological%20News%20Bulletin/ENB%20Quarterly_Jul%202017%20Vol%
2043%20No.3%20(Final).pdf
9. Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, et al. Role of pneumococcal vaccination in prevention
of pneumococcal disease among adults in Singapore. Int J Gen Med. Dove Press; 2014; 7: 179–191.
https://doi.org/10.2147/IJGM.S54963 PMID: 24729726
10. Singapore SOID. Clinical Practice Guidelines on Adult Vaccination in Singapore. 1st ed. Singa-
pore:2016. [Internet]. URL:http://ams.edu.sg/view—pdf.aspx?file=media%5C3075_fi_366.pdf&ofile=
Adult%2BVaccination%2BGuidelines_HR2+One+PDF.pdf
11. How CH, Phua See Chun P, Shafi F, Jakes RW. Parental knowledge, attitudes and perception of pneu-
mococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assess-
ment. BMC Public Health. BioMed Central; 2016; 16: 923. https://doi.org/10.1186/s12889-016-3597-5
PMID: 27590503
12. Paterson DL, Ko WC, Gottberg von A, Mohapatra S, Casellas JM, Goossens H, et al. International pro-
spective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-
Pneumococcal infection in adults and children in Singapore
PLOS ONE | https://doi.org/10.1371/journal.pone.0220951 October 16, 2019 15 / 17
lactamase production in nosocomial Infections. Ann Intern Med. 2004; 140: 26–32. https://doi.org/10.
7326/0003-4819-140-1-200401060-00008 PMID: 14706969
13. CLSI. M100-S24: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Infor-
mational Supplement. 2014 Jan pp. 1–230.
14. Navarro-Torne´ A, Dias JG, Hruba F, Lopalco PL, Pastore-Celentano L, Gauci AJA, et al. Risk factors
for death from invasive pneumococcal disease, Europe, 2010. Emerging Infect Dis. 2015; 21: 417–425.
https://doi.org/10.3201/eid2103.140634 PMID: 25693604
15. Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study
of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical
outcome. Clin Infect Dis. Oxford University Press; 2003; 37: 230–237. https://doi.org/10.1086/377534
PMID: 12856216
16. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974; 19: 716–
723. https://doi.org/10.1109/TAC.1974.1100705
17. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiol-
ogy of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Strepto-
coccus pneumoniae research (CASPER) study. Clin Infect Dis. Oxford University Press; 2009; 49:
205–212. https://doi.org/10.1086/599827 PMID: 19508165
18. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conju-
gate vaccine on pneumococcal meningitis. N Engl J Med. Massachusetts Medical Society; 2009; 360:
244–256. https://doi.org/10.1056/NEJMoa0800836 PMID: 19144940
19. Health SMO. Communicable Diseases Surveillance in Singapore 2012 [Internet]. https://www.moh.gov.
sg/docs/librariesprovider5/resources-statistics/reports/childhood-
immunisationf0f0fb82a2a143718a25f214f300a71d.pdf
20. Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA. Postvaccination increase in serotype 19A pneu-
mococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 com-
plex. Clin Vaccine Immunol. 2012; 19: 443–445. https://doi.org/10.1128/CVI.05563-11 PMID:
22237889
21. Andam CP, Mitchell PK, Callendrello A, Chang Q, Corander J, Chaguza C, et al. Genomic Epidemiol-
ogy of Penicillin-Nonsusceptible Pneumococci with Nonvaccine Serotypes Causing Invasive Disease in
the United States. Richter SS, editor. J Clin Microbiol. 2017; 55: 1104–1115. https://doi.org/10.1128/
JCM.02453-16 PMID: 28100596
22. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High Prevalence of Antimicrobial Resis-
tance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). Antimicrob
Agents Chemother. 2004; 48: 2101–2107. https://doi.org/10.1128/AAC.48.6.2101-2107.2004 PMID:
15155207
23. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns
among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on
3 continents. Diagn Microbiol Infect Dis. Elsevier; 2006; 56: 427–436. https://doi.org/10.1016/j.
diagmicrobio.2006.07.003 PMID: 16938419
24. Vasoo S, Singh K, Hsu LY, Chiew YF, Chow C, Lin RTP, et al. Increasing antibiotic resistance in Strep-
tococcus pneumoniae colonizing children attending day-care centres in Singapore. Respirology. Black-
well Publishing Asia; 2011; 16: 1241–1248. https://doi.org/10.1111/j.1440-1843.2011.02036.x PMID:
21848708
25. Chong CY, Koh-Cheng T, Yee-Hui M, Nancy TW-S. Invasive pneumococcal disease in Singapore chil-
dren. Vaccine. 2008; 26: 3427–3431. https://doi.org/10.1016/j.vaccine.2008.04.035 PMID: 18499309
26. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppa¨la¨ H, Finnish Study Group for Antimicrobial
Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resis-
tance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006; 50: 3646–3650. https://doi.
org/10.1128/AAC.00234-06 PMID: 16940064
27. Dagan R, Barkai G, Leibovitz E, Dreifuss E, Greenberg D. Will reduction of antibiotic use reduce antibi-
otic resistance?: The pneumococcus paradigm. Pediatr Infect Dis J. 2006; 25: 981–986. https://doi.org/
10.1097/01.inf.0000239266.20642.26 PMID: 17006311
28. Ekdahl K, Ahlinder I, Hansson HB, Melander E, Mo¨lstad S, So¨derstro¨m M, et al. Duration of nasopha-
ryngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish
Pneumococcal Intervention Project. Clin Infect Dis. 1997; 25: 1113–1117. https://doi.org/10.1086/
516103 PMID: 9402367
29. Lynch JP, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir
Crit Care Med.© Thieme Medical Publishers; 2009; 30: 210–238. https://doi.org/10.1055/s-0029-
1202939 PMID: 19296420
Pneumococcal infection in adults and children in Singapore
PLOS ONE | https://doi.org/10.1371/journal.pone.0220951 October 16, 2019 16 / 17
30. Thoon KC, Chong CY, Tee NWS. Early impact of pneumococcal conjugate vaccine on invasive pneu-
mococcal disease in Singapore children, 2005 through 2010. Int J Infect Dis. Elsevier; 2012; 16: e209–
15. https://doi.org/10.1016/j.ijid.2011.11.014 PMID: 22281191
31. Imran MN, Leng PH, Yang S, Kurup A, Eng P. Early predictors of mortality in pneumococcal bacterae-
mia. Ann Acad Med Singap. 2005; 34: 426–431. PMID: 16123815
32. Alanee SRJ, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al. Association of serotypes of
Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin
Infect Dis. Oxford University Press; 2007; 45: 46–51. https://doi.org/10.1086/518538 PMID: 17554699
33. Low S, Chan FLF, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumo-
coccal disease among hospitalised patients in Singapore: 1995 to 2004. Singapore Med J. 2007; 48:
824–829. PMID: 17728963
34. Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, et al. Epidemiology and
outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Euro Surveill. 2014;
19: 14–22.
35. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from inva-
sive Streptococcus pneumoniae disease revisited. BMC Infectious Diseases. BioMed Central; 2004; 4:
21. https://doi.org/10.1186/1471-2334-4-21 PMID: 15228629
36. Klemets P, Lyytika¨inen O, Ruutu P, Ollgren J, Nuorti JP. Invasive pneumococcal infections among per-
sons with and without underlying medical conditions: implications for prevention strategies. BMC Infec-
tious Diseases. BioMed Central; 2008; 8: 96. https://doi.org/10.1186/1471-2334-8-96 PMID: 18647385
Pneumococcal infection in adults and children in Singapore
PLOS ONE | https://doi.org/10.1371/journal.pone.0220951 October 16, 2019 17 / 17
